Data Disclosure Form												
											Date of publication: 23/06/2022	
											Transparency Report 202	L Jazz Pharmaceuticals
	Full name	Full name HCPs: City of Principal Practice HCOs: city Principal Principal Principal Practice Address Unique country identifier OPTIONAL Practice				Contribution to costs of Events			Fee for service and consultancy			TOTAL (OPTIONAL)
					Grants to HCOs	Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract including travel & accommodation relevant to the contract		
	NDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: Itemization should be available for the individual Recipient or public authorities 'consultation only, as appropriate)											
	Elisabeth Wallhult	Göteborg	Sweden Bruna Stråket 5						12863			12863
CPs	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons											
Ŧ	Aggregate amount attributable to transfers of value to such Recipients						0	0	0	0		0
	Number of Recipients in aggregate disclosure						0	0	0	0		0
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed						0%	0%	0%	0%		
	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual H							ities' consultation on	y, as appropriate)	1		
	Karolinska Institutet	Stockholm	Sweden Nobels Väg 6			72132		I		I		72132
ő	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons								T	1		
Ŧ	Aggregate amount attributable to transfers of value to such Recipients Number of Recipients in aggregate disclosure				0	0	0	0	0	0	-	
						0	0	0	0	0	-	
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed					0%	0%	0%	0%	0%		
a AGGREGATE DISCLOSURE												
L SC		Transfers of Value re Research & Development as defined										0
											1	J